Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Keytruda, Revlimid, and Decadron as consolidation in high-risk multiple myeloma
NCT02906332Phase 2Terminated
- Sponsor
- Hackensack Meridian Health
- Start
- Dec 2016
- Primary completion
- May 2022
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in multiple myeloma (MM), sponsored by Hackensack Meridian Health. Started Dec 2016; status: terminated.
02
Drugs
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT02906332.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02906332.